Novel P2 Tris-tetrahydrofuran Group in Antiviral Compound 1 (GRL-0519) Fills the S2 Binding Pocket of Selected Mutants of HIV-1 Protease

被引:26
作者
Zhang, Hongmei [1 ]
Wang, Yuan-Fang [1 ]
Shen, Chen-Hsiang [1 ]
Agniswamy, Johnson [1 ]
Rao, Kalapala Venkateswara [4 ,5 ]
Xu, Chun-Xiao [4 ,5 ]
Ghosh, Arun K. [4 ,5 ]
Harrison, Robert W. [1 ,2 ]
Weber, Irene T. [1 ,3 ]
机构
[1] Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA
[2] Georgia State Univ, Dept Comp Sci, Mol Basis Dis Program, Atlanta, GA 30303 USA
[3] Georgia State Univ, Dept Chem, Mol Basis Dis Program, Atlanta, GA 30303 USA
[4] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA
[5] Purdue Univ, Dept Med Chem, W Lafayette, IN 47907 USA
基金
美国国家卫生研究院;
关键词
RESOLUTION CRYSTAL-STRUCTURES; DRUG-RESISTANT MUTANTS; HUMAN-IMMUNODEFICIENCY; MULTIDRUG-RESISTANCE; MUTATIONS; NELFINAVIR; INHIBITORS; STABILITY; L90M; V82A;
D O I
10.1021/jm301519z
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
GRL-0519 (1) is a potent antiviral inhibitor of HIV-1 protease (PR) possessing tris-tetrahydrofuran (tris-THF) at P2. The high resolution X-ray crystal structures of inhibitor 1 in complexes with single substitution mutants PRR8Q, PRD30N, PR150V, PR154M, and PRV82A were analyzed in relation to kinetic data. The smaller valine side chain in PR150V eliminated hydrophobic interactions with inhibitor and the other subunit consistent with 60-fold worse inhibition. Asn30 in PRD30N showed altered interactions with neighboring residues and 18-fold worse inhibition. Mutations V82A and I54M showed compensating structural changes consistent with 6-7-fold lower inhibition. Gln8 in PRR8Q replaced the ionic interactions of wild type Arg8 with hydrogen bond interactions without changing the inhibition significantly. The carbonyl oxygen of Gly48 showed two alternative conformations in all structures likely due to the snug fit of the large tris-THF group in the S2 subsite in agreement with high antiviral efficacy of 1 on resistant virus.
引用
收藏
页码:1074 / 1083
页数:10
相关论文
共 41 条
  • [1] HIV-1 Protease with 20 Mutations Exhibits Extreme Resistance to Clinical Inhibitors through Coordinated Structural Rearrangements
    Agniswamy, Johnson
    Shen, Chen-Hsiang
    Aniana, Annie
    Sayer, Jane M.
    Louis, John M.
    Weber, Irene T.
    [J]. BIOCHEMISTRY, 2012, 51 (13) : 2819 - 2828
  • [2] HIV-1 drug resistance: can we overcome?
    Brenner, BG
    Turner, D
    Wainberg, MA
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (07) : 751 - 761
  • [3] Potent Antiviral HIV-1 Protease Inhibitor GRL-02031 Adapts to the Structures of Drug Resistant Mutants with Its P1′-Pyrrolidinone Ring
    Chang, Yu-Chung E.
    Yu, XiaXia
    Zhang, Ying
    Tie, Yunfeng
    Wang, Yuan-Fang
    Yashchuk, Sofiya
    Ghosh, Arun K.
    Harrison, Robert W.
    Weber, Irene T.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (07) : 3387 - 3397
  • [4] HIV-1 PROTEASE SPECIFICITY OF PEPTIDE CLEAVAGE IS SUFFICIENT FOR PROCESSING OF GAG AND POL POLYPROTEINS
    DARKE, PL
    NUTT, RF
    BRADY, SF
    GARSKY, VM
    CICCARONE, TM
    LEU, CT
    LUMMA, PK
    FREIDINGER, RM
    VEBER, DF
    SIGAL, IS
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 156 (01) : 297 - 303
  • [5] Coot:: model-building tools for molecular graphics
    Emsley, P
    Cowtan, K
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2004, 60 : 2126 - 2132
  • [6] Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere
    Ghosh, AK
    Kincaid, JF
    Cho, WH
    Walters, DE
    Krishnan, K
    Hussain, KA
    Koo, Y
    Cho, H
    Rudall, C
    Holland, L
    Buthod, J
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (06) : 687 - 690
  • [7] Probing Multidrug-Resistance and Protein-Ligand Interactions with Oxatricyclic Designed Ligands in HIV-1 Protease Inhibitors
    Ghosh, Arun K.
    Xu, Chun-Xiao
    Rao, Kalapala Venkateswara
    Baldridge, Abigail
    Agniswamy, Johnson
    Wang, Yuan-Fang
    Weber, Irene T.
    Aoki, Manabu
    Miguel, Salcedo Gomez Pedro
    Amano, Masayuki
    Mitsuya, Hiroaki
    [J]. CHEMMEDCHEM, 2010, 5 (11) : 1850 - 1854
  • [8] HIV/AIDS Vaccines: A Need for New Concepts?
    Girard, Marc P.
    Bansal, Geetha P.
    [J]. INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2008, 27 (06) : 447 - 471
  • [9] Interplay between Single Resistance-Associated Mutations in the HIV-1 Protease and Viral Infectivity, Protease Activity, and Inhibitor Sensitivity
    Henderson, Gavin J.
    Lee, Sook-Kyung
    Irlbeck, David M.
    Harris, Janera
    Kline, Melissa
    Pollom, Elizabeth
    Parkin, Neil
    Swanstrom, Ronald
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (02) : 623 - 633
  • [10] CHARACTERIZATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS WITH INCREASED RESISTANCE TO A C-2-SYMMETRICAL PROTEASE INHIBITOR
    HO, DD
    TOYOSHIMA, T
    MO, HM
    KEMPF, DJ
    NORBECK, D
    CHEN, CM
    WIDEBURG, NE
    BURT, SK
    ERICKSON, JW
    SINGH, MK
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (03) : 2016 - 2020